Chris Boshoff: Excited to step into a new role as Pfizer’s Chief Scientific Officer and President Research and Development
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared a post on LinkedIn:
“I’m excited to step into a new role in January as Pfizer’s Chief Scientific Officer and President R&D. Following Mikael Dolsten’s departure announcement earlier this year, I am honored to expand my Oncology role, taking on leadership of a combined R&D organization that includes world-class talent and capabilities, industry leading success rates and cycle times, and a promising pipeline of innovative medicines and vaccine candidates poised to have a tremendous impact for patients globally.
With these changes, I’m also thrilled to share that Dr. Roger Dansey has been named as Chief Oncology Officer. Our end-to-end Oncology unit will maintain its fully integrated structure under Roger’s leadership. After joining Pfizer through the Seagen acquisition, Roger has served as the Chief Development Officer, Oncology. Roger is a terrific leader with enormous contributions over many decades to science and to patients with cancer. At Seagen, he served as Chief Medical Officer since 2018 and interim CEO in 2022, and previously, he led Clinical Oncology Research at Merck.
I look forward to continuing to work with all of our stakeholders, including our patient advocacy groups, biotech partners, health authorities, health care providers, academic and community centers, and our entire R&D organization to deliver even more breakthroughs to patients around the world.
Click here to read more.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023